These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 24055835)

  • 1. Insights into susceptibility of antiviral drugs against the E119G mutant of 2009 influenza A (H1N1) neuraminidase by molecular dynamics simulations and free energy calculations.
    Pan P; Li L; Li Y; Li D; Hou T
    Antiviral Res; 2013 Nov; 100(2):356-64. PubMed ID: 24055835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding of known drug-target interactions in the catalytic pocket of neuraminidase subtype N1.
    Malaisree M; Rungrotmongkol T; Decha P; Intharathep P; Aruksakunwong O; Hannongbua S
    Proteins; 2008 Jun; 71(4):1908-18. PubMed ID: 18175324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Theoretical studies on the susceptibility of oseltamivir against variants of 2009 A/H1N1 influenza neuraminidase.
    Li L; Li Y; Zhang L; Hou T
    J Chem Inf Model; 2012 Oct; 52(10):2715-29. PubMed ID: 22998323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic behavior of avian influenza A virus neuraminidase subtype H5N1 in complex with oseltamivir, zanamivir, peramivir, and their phosphonate analogues.
    Udommaneethanakit T; Rungrotmongkol T; Bren U; Frecer V; Stanislav M
    J Chem Inf Model; 2009 Oct; 49(10):2323-32. PubMed ID: 19780597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infiltration of water molecules into the oseltamivir-binding site of H274Y neuraminidase mutant causes resistance to oseltamivir.
    Park JW; Jo WH
    J Chem Inf Model; 2009 Dec; 49(12):2735-41. PubMed ID: 19957991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico identification of the potential drug resistance sites over 2009 influenza A (H1N1) virus neuraminidase.
    Liu H; Yao X; Wang C; Han J
    Mol Pharm; 2010 Jun; 7(3):894-904. PubMed ID: 20420444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the cross-resistance of oseltamivir to H1N1 and H5N1 influenza A neuraminidase mutations using multidimensional computational analyses.
    Singh A; Soliman ME
    Drug Des Devel Ther; 2015; 9():4137-54. PubMed ID: 26257512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular basis of drug resistance in A/H1N1 virus.
    Vergara-Jaque A; Poblete H; Lee EH; Schulten K; González-Nilo F; Chipot C
    J Chem Inf Model; 2012 Oct; 52(10):2650-6. PubMed ID: 22978683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long time scale GPU dynamics reveal the mechanism of drug resistance of the dual mutant I223R/H275Y neuraminidase from H1N1-2009 influenza virus.
    Woods CJ; Malaisree M; Pattarapongdilok N; Sompornpisut P; Hannongbua S; Mulholland AJ
    Biochemistry; 2012 May; 51(21):4364-75. PubMed ID: 22574858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.
    Fujisaki S; Takashita E; Yokoyama M; Taniwaki T; Xu H; Kishida N; Sato H; Tashiro M; Imai M; Odagiri T
    Biochem Biophys Res Commun; 2012 Dec; 429(1-2):51-6. PubMed ID: 23131559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural analysis of the novel influenza A (H7N9) viral Neuraminidase interactions with current approved neuraminidase inhibitors Oseltamivir, Zanamivir, and Peramivir in the presence of mutation R289K.
    Tran-To Su C; Ouyang X; Zheng J; Kwoh CK
    BMC Bioinformatics; 2013; 14 Suppl 16(Suppl 16):S7. PubMed ID: 24564719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding pattern of the long acting neuraminidase inhibitor laninamivir towards influenza A subtypes H5N1 and pandemic H1N1.
    Meeprasert A; Khuntawee W; Kamlungsua K; Nunthaboot N; Rungrotmongkol T; Hannongbua S
    J Mol Graph Model; 2012 Sep; 38():148-54. PubMed ID: 23079644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation-induced loop opening and energetics for binding of tamiflu to influenza N8 neuraminidase.
    Kar P; Knecht V
    J Phys Chem B; 2012 May; 116(21):6137-49. PubMed ID: 22553951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
    Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H
    Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
    Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI
    Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in neuraminidase inhibitor development as anti-influenza drugs.
    Feng E; Ye D; Li J; Zhang D; Wang J; Zhao F; Hilgenfeld R; Zheng M; Jiang H; Liu H
    ChemMedChem; 2012 Sep; 7(9):1527-36. PubMed ID: 22807317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico study on multidrug resistance conferred by I223R/H275Y double mutant neuraminidase.
    Tan H; Wei K; Bao J; Zhou X
    Mol Biosyst; 2013 Nov; 9(11):2764-74. PubMed ID: 24056678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds.
    Abed Y; Baz M; Boivin G
    Antivir Ther; 2006; 11(8):971-6. PubMed ID: 17302366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus.
    Wang SQ; Du QS; Huang RB; Zhang DW; Chou KC
    Biochem Biophys Res Commun; 2009 Aug; 386(3):432-6. PubMed ID: 19523442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir.
    Tamura D; DeBiasi RL; Okomo-Adhiambo M; Mishin VP; Campbell AP; Loechelt B; Wiedermann BL; Fry AM; Gubareva LV
    J Infect Dis; 2015 Oct; 212(8):1209-13. PubMed ID: 25943200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.